000281644 001__ 281644
000281644 005__ 20251111133745.0
000281644 0247_ $$2doi$$a10.3389/fimmu.2025.1648946
000281644 0247_ $$2pmid$$apmid:41064005
000281644 0247_ $$2pmc$$apmc:PMC12500446
000281644 037__ $$aDZNE-2025-01162
000281644 041__ $$aEnglish
000281644 082__ $$a610
000281644 1001_ $$avon Zedtwitz, Katharina$$b0
000281644 245__ $$aMorphometric MRI findings in patients with suspected autoimmune psychosis spectrum syndromes and association with EEG slowing, CSF changes, and psychometric/neuropsychological findings.
000281644 260__ $$aLausanne$$bFrontiers Media$$c2025
000281644 3367_ $$2DRIVER$$aarticle
000281644 3367_ $$2DataCite$$aOutput Types/Journal article
000281644 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1762864405_6255
000281644 3367_ $$2BibTeX$$aARTICLE
000281644 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000281644 3367_ $$00$$2EndNote$$aJournal Article
000281644 520__ $$aPatients with autoimmune encephalitis - who often have accompanying psychiatric symptoms - frequently have electroencephalography (EEG) changes and normal conventional magnetic resonance imaging (MRI) findings. The aim of this paper was to analyze automated EEG and morphometric MRI findings in psychiatric patients with suspected autoimmune psychosis (AP) spectrum syndromes versus controls and the correlation of MRI measures with EEG, cerebrospinal fluid (CSF), and psychometric/neuropsychological findings.In total, forty patients were included. Suspected AP spectrum syndromes were defined broadly based on the autoimmune psychiatric syndrome concept. All patients showed signs of an autoimmune process. That is, upon further diagnostic testing, they tested at least positive for well-characterized neuronal antibodies, novel central nervous system antibodies, or well-characterized systemic antibodies with brain involvement. For EEG, thirty-seven matched patient-control pairs, and for structural MRI, thirty-five patients and matched controls, were available. EEG analysis for intermittent rhythmic delta/theta activity (IRDA/IRTA) was performed using independent component analysis. MRI scans were analyzed using FreeSurfer (7.2) for the subcortical measures and CAT12 for cortical thickness and global volumes.Patients did not show significantly increased IRDA/IRTA rates. Regarding brain volumes, there was a significant decrease in grey matter volume/total intracranial volume (TIV) (p=0.027) and a significant increase in CSF/TIV (p=0.027), which remained significant after correction for multiple comparisons. Further differences with lower white matter volume/TIV, reduced cortical thickness in the left parahippocampal and transversotemporal gyri and an increase in the volume of the left lateral ventricle of patients did not remain significant after correcting for multiple testing. White blood cell counts in the CSF of the whole patient group correlated positively with increased hippocampal volumes. Brain volumes did not correlate with psychometric scales, but with several neuropsychological scores.Autoantibody-associated suspected AP spectrum syndromes seem to be associated with slight global grey matter volume reductions and secondary increased CSF volumes. Associations between hippocampal volume increases and inflammatory CSF markers could, in contrast, reflect edematous swelling within the limbic system. Further multimodal imaging studies of more homogeneous AP groups might be promising to detect morphometric correlates.
000281644 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000281644 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000281644 650_7 $$2Other$$aautoantibody
000281644 650_7 $$2Other$$abrain
000281644 650_7 $$2Other$$acortical thickness
000281644 650_7 $$2Other$$aneuroinflammation
000281644 650_7 $$2Other$$astructural MRI
000281644 650_2 $$2MeSH$$aHumans
000281644 650_2 $$2MeSH$$aFemale
000281644 650_2 $$2MeSH$$aMale
000281644 650_2 $$2MeSH$$aElectroencephalography
000281644 650_2 $$2MeSH$$aMagnetic Resonance Imaging
000281644 650_2 $$2MeSH$$aAdult
000281644 650_2 $$2MeSH$$aPsychotic Disorders: diagnostic imaging
000281644 650_2 $$2MeSH$$aPsychotic Disorders: physiopathology
000281644 650_2 $$2MeSH$$aPsychotic Disorders: psychology
000281644 650_2 $$2MeSH$$aPsychotic Disorders: diagnosis
000281644 650_2 $$2MeSH$$aPsychotic Disorders: immunology
000281644 650_2 $$2MeSH$$aMiddle Aged
000281644 650_2 $$2MeSH$$aPsychometrics
000281644 650_2 $$2MeSH$$aBrain: diagnostic imaging
000281644 650_2 $$2MeSH$$aBrain: physiopathology
000281644 650_2 $$2MeSH$$aNeuropsychological Tests
000281644 650_2 $$2MeSH$$aYoung Adult
000281644 7001_ $$aTebartz van Elst, Ludger$$b1
000281644 7001_ $$aFeige, Bernd$$b2
000281644 7001_ $$aMatteit, Isabelle$$b3
000281644 7001_ $$aSchlump, Andrea$$b4
000281644 7001_ $$aLange, Thomas$$b5
000281644 7001_ $$aRunge, Kimon$$b6
000281644 7001_ $$aNickel, Kathrin$$b7
000281644 7001_ $$aVenhoff, Nils$$b8
000281644 7001_ $$aDomschke, Katharina$$b9
000281644 7001_ $$0P:(DE-2719)2810931$$aPrüss, Harald$$b10$$udzne
000281644 7001_ $$aRau, Alexander$$b11
000281644 7001_ $$aReisert, Marco$$b12
000281644 7001_ $$aMaier, Simon J$$b13
000281644 7001_ $$aEndres, Dominique$$b14
000281644 773__ $$0PERI:(DE-600)2606827-8$$a10.3389/fimmu.2025.1648946$$gVol. 16, p. 1648946$$p1648946$$tFrontiers in immunology$$v16$$x1664-3224$$y2025
000281644 8564_ $$uhttps://pub.dzne.de/record/281644/files/DZNE-2025-01162.pdf$$yOpenAccess
000281644 8564_ $$uhttps://pub.dzne.de/record/281644/files/DZNE-2025-01162.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000281644 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810931$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b10$$kDZNE
000281644 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000281644 9141_ $$y2025
000281644 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-28
000281644 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-28
000281644 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000281644 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT IMMUNOL : 2022$$d2024-12-28
000281644 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-12-29T15:23:07Z
000281644 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-12-29T15:23:07Z
000281644 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-28
000281644 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2024-12-28
000281644 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-28
000281644 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000281644 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-12-29T15:23:07Z
000281644 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2024-12-28
000281644 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bFRONT IMMUNOL : 2022$$d2024-12-28
000281644 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-28
000281644 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-28
000281644 9201_ $$0I:(DE-2719)1810003$$kAG Prüß$$lAutoimmune Encephalopathies$$x0
000281644 980__ $$ajournal
000281644 980__ $$aVDB
000281644 980__ $$aUNRESTRICTED
000281644 980__ $$aI:(DE-2719)1810003
000281644 9801_ $$aFullTexts